🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lishui
Clinical trial register · China

Clinical Trials in Lishui, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Yu jiren5 Second Affiliated Hospital, Zhejiang University, School of Medicine4 Eli Lilly and Company3 Zhejiang Cancer Hospital2 Zhejiang University2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Lishui

41 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)
NCT07800572Acute Ischemic Stroke
Capital Medical University
Phase 2
204
Anyang, Beijing, Huzhou, Jiuquan, Lishui, Shangqiu, Suzhou, Taizhou
2026-09-06
Recruiting
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
NCT07754812NSCLC (Non-small Cell Lung Cancer)
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
78
Guangzhou, Suqian, Shanghai, Hangzhou, Lishui
2026-06-25
Recruiting
Whole-life Investigation of Lishui Longevity
NCT07592962Ischemic Stroke, Chronic Disease, Cardiovascular
The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital
Observational
4,500
Lishui
2026-05-18
Recruiting
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
NCT07479485Hepatocellular Carcinoma
Lepu Biopharma Co., Ltd.
Phase 1/2
160
Beijing, Fuzhou, Zhengzhou, Nanjing, Tianjin, Lishui
2026-04-08
Recruiting
Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion
NCT07185022Stroke, Cerebrovascular Disorders, Brain Diseases, Nervous System Diseases
The Second Hospital of Anhui Medical University
Not applicable
282
Fuyang, Hefei, Lu'an, Liuzhou, Lishui
2026-01-06
Active, closed
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years
NCT07281677HPV Infection
Zhejiang Provincial Center for Disease Control and Prevention
Phase 4
400
Lishui
2025-12-20
Recruiting
Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
NCT07175155Hypoxemia, Esophageal Cancer, Morbidly Obese Patients, Gastric Cancer
Zhejiang University
Not applicable
410
Beijing, Jinjiang, Hangzhou, Lishui, Taizhou
2025-10-24
Recruiting
The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial.
NCT07335536Hypoxia, Infertility, Infertility Assisted Reproductive Technology
Diansan Su
Not applicable
400
Dongyang, Hangzhou, Lishui
2025-10-20
Recruiting
Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy
NCT07104214Gastric Cancer Stage, Esophageal Cancer, Gastroparesis
Zhejiang University
Observational
5,000
Hangzhou, Jiaxing, Lishui
2025-08-03
Recruiting
Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycystic Ovary Syndrome
NCT07106996Polycystic Ovary Syndrome (PCOS)
Sichuan Provincial People's Hospital
Phase EARLY_PHASE1
90
Lishui
2025-07-28
Recruiting
Effectiveness of DITM Versus IMT in COPD Patients
NCT06958666COPD (Chronic Obstructive Pulmonary Disease)
Sir Run Run Shaw Hospital
Not applicable
410
Hangzhou, Lishui, Taizhou
2025-06-30
Recruiting
Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases
NCT07117435Colorectal Liver Metastases, First-line Treatment
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1
7
Lishui
2025-05-13
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
Eli Lilly and Company
Phase 3
487
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
Eli Lilly and Company
Phase 3
974
Beijing, Changchun, Changde, Chengdu, Chongqing, Jinan, Lishui, Luoyang Shi
2025-04-30
Recruiting
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
NCT06844357HCC
Zhejiang Raygene Pharmaceuticals Co., Ltd
Phase 2/3
300
Nanjing, Lishui
2025-03-27
Recruiting
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
NCT07022223Marginal Zone Lymphoma(MZL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
51
Hangzhou, Dongyang, Huzhou, Jiaxing, Lishui, Ningbo, Quzhou, Shaoxing
2025-03-11
Recruiting
A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome
NCT06955143Acute Coronary Syndrome, Chronic Coronary Syndrome
Second Affiliated Hospital of Wenzhou Medical University
Observational
310
Lishui
2025-03-11
Recruiting
Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma
NCT06801730Glioma
Zhifeng Tian,MD
Phase 2
38
Lishui
2025-01-08
Not yet open
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
NCT06779461Hepatocellular Carcinoma Non-Resectable
InnoBM Pharmaceuticals Co., Ltd.
Phase 3
228
Bengbu, Anyang, Zhengzhou, Nanjing, Lishui, Guangzhou, Lanzhou, Luoyang
2025-01
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
Basilea Pharmaceutica
Phase 3
450
Beijing, Bengbu, Chengdu, Guangzhou, Hangzhou, Lishui, Liuzhou, Nanchang
2024-12-11
Recruiting
A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring
NCT06792786Esophageal Cancer, ctDNA
The Central Hospital of Lishui City
Not applicable
30
Jinhua, Lishui
2024-12-10
Recruiting
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
NCT06520163Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08-01
Recruiting
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
NCT06520176Multiple Myeloma, Hematopoietic Stem Cell Mobilization
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08
Not yet open
Reverse Drilling Technique in Improving Outcomes After Arthroscopic Anterior Cruciate Ligament Reconstruction
NCT05994872Anterior Cruciate Ligament Injuries
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
216
Huzhou, Lishui, Meicheng, Ningbo, Shaoxing, Taizhou
2024-05-31
Active, closed
Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis
NCT06365697Carotid Artery Stenosis
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
188
Shenyang, Linyi, Qingdao, Jinan, Lishui, Beijing
2024-04-24
Recruiting
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
NCT05872685Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair
Yu jiren
Phase 2
314
Hangzhou, Lishui, Ningbo, Taizhou
2023-12-24
Recruiting
Clinical Study of Single Incision Laparoscopic Cholecystectomy in the Treatment of Patients With Acute Cholecystitis
NCT06074679Cholecystectomy, Laparoscopic
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
600
Huangshan City, Hangzhou, Huzhou, Lishui, Meicheng
2023-10-01
Recruiting
Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study
NCT06114784Severe Pneumonia
First Affiliated Hospital of Zhejiang University
Observational
2,000
Hangzhou, Huzhou, Jiaxing, Lanxi, Lishui, Pinghu, Taizhou, Wenzhou
2023-09-25
Not yet open
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05970627Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Epstein-Barr Virus-Associated Gastric Carcinoma
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-07-28
Recruiting
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05729646Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Mismatch Repair Deficiency
Yu jiren
Phase 2
90
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-31
Active, closed
Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
NCT05715931Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, HER2-positive Gastric Cancer
Yu jiren
Phase 2
30
Hangzhou, Huzhou, Lishui, Ningbo, Taizhou
2023-05-30
Recruiting
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
NCT05652920Hepatocellular Carcinoma
OriCell Therapeutics Co., Ltd.
Phase 1/2
105
Beijing, Changsha, Changchun, Chengdu, Hangzhou, Lishui, Shanghai
2022-12-15
Recruiting
Radiotherapy Combined With Endostatin and Capecitabine for NPC
NCT05514275Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
41
Hangzhou, Jiaxing, Jinhua, Lishui, Ningbo, Quzhou
2022-08-01
Active, closed
The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT.
NCT05797714HBV Infection, Chronic Hepatitis b
Ruijin Hospital
Not applicable
200
Changsha, Beijing, Dongyang, Fuyang, Hangzhou, Lishui, Nanchang, Nanjin
2022-06-08
Recruiting
Westlake Longevity Cohort
NCT05256251Aging
Westlake University
Observational
1,500
Lishui
2021-11-15
Recruiting
Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer
NCT04974346Cervical Cancer
Zhejiang Cancer Hospital
Phase 3
455
Hangzhou, Jinhua, Lishui, Ningbo, Taizhou, Wanzhou
2021-08-02
Recruiting
China Longitudinal Aging and Cognitive Impairment Study
NCT05468905Aging, Mild Cognitive Impairment, Alzheimer Disease, Neurodegeneration
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
4,000
Hangzhou, Lishui
2021-01-10
Active, closed
Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
NCT04515615Gastric Cancer Stage III
Yu jiren
Phase 2
52
Hangzhou, Lishui, Taizhou, Wenzhou
2020-09-09
Recruiting
Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis
NCT04158843Breast Cancer, Oligometastasis
xuexin he
Not applicable
183
Hangzhou, Jiaxing, Lishui
2020-05-09
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Beijing, Chongqing, Jiamusi, Ji’an, Kaifeng, Liaocheng, Lishui, Nanchang
2016-12
Rows per page Showing 1–41 of 41
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/lishui

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 41 of those studies with a site in Lishui.

How many clinical trials are recruiting in Lishui?

30 of the 41 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lishui), 41 studies
PhaseStudiesRecruitingShare
Not applicable10724.4%
Phase 29622%
Phase 38419.5%
Observational7717.1%
Phase 1/2224.9%
Phase 4214.9%
Phase 1112.4%
Phase 2/3112.4%
Phase EARLY_PHASE1112.4%

Most active sponsors

Lead sponsors with the most studies (Lishui)
Lead sponsorStudiesRecruiting
Yu jiren52
Second Affiliated Hospital, Zhejiang University, School of Medicine43
Eli Lilly and Company30
The Affiliated People's Hospital of Ningbo University22
Zhejiang Cancer Hospital22
Zhejiang University22
Basilea Pharmaceutica11
Capital Medical University11
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.11
Diansan Su11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.